Updated Research Opportunities

The new list of research opportunities at the core center in Westchester is out. Check the new list to see if you are interested in participating in any of them.

To learn more about any studies, please contact Armando Ramirez, Senior Research Coordinator, at Armando_ramirez@bchphysicians.org, or 914-504-0152

STUDY (click for full study details) BRIEF STUDY DESCRIPTION	BRIEF PARTICIPANT CRITERIA
Phase 1 Study Evaluating Safety and Tolerability of RCT2100 in Health Participants and Participants with CF New mRNA Therapy for CF	18-60 years old FEV1 50%-100% Not genetically eligible for or not taking modulators (exclusions apply)
Phase 1 Study of Inhaled KB407, a Replication-Defective, Non-Integrating Vector Expressing  Human Cystic Fibrosis Transmembrane Conductance Regulator, for the Treatment of CF  New inhaled CFTR (HSV-1)-derived vector for CF	≥18 years old FEV1 50%-100% Not genetically eligible for modulators
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study (STOP360AG) One IV Antibiotic v. Two IV Antibiotics for treatment of Pulmonary Exacerbation with Pseudomonas	≥6 years old Needing treatment for a CF pulmonary exacerbation with IV antibiotics
Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators (REACH)  Observational Study For People With CF Not Taking Modulators	≥18 years old Not currently taking modulators
Phase 2a Randomized, Double-blind, Placebo-controlled Proof-of-concept Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of SION-719 When Added to Physician-prescribed Trikafta® in People With CF Who Are Homozygous for F508del Mutation New Add-On Therapy for People with CF Taking Trikafta®	≥18 years old F508del homozygous FEV1 40%-100% Currently taking Trikafta
Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy,  Safety, and Tolerability of BI 1291583 2.5 mg Administered Once Daily for up to 76 Weeks in Patients With Bronchiectasis (The AIRTIVITY® Study) New Medicine for both CF and Non-CF Bronchiectasis	≥18 years old Confirmed bronchiectasis At least one pulmonary exacerbations requiring antibiotics in last 12 months
Phase 1, Study of VX-828 in Healthy Subjects and in Subjects With CF  New Modulator for CF	≥18 years old Heterozygous F508del with second variant non-responsive to Trikafta FEV1  ≥40%